RE: Vlads Tweet...28 Oct 2022 11:38
People questioning target sp should look at other small pharma in this field, take a look at autolus, pre-clinical and phase 1 only, multiple trials same product. MCap 270mil. That covers HEMO-CAR-T alone.
Potential from CBR is much much bigger!!